Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective study of upadacitinib in inflammatory bowel disease
ChiCTR2300075317Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Effectiveness (clinical and endoscopic disease activity at one year). Planned start Sep 2023; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ChiCTR2300075317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075317.